Insulin Resistance and Type 2 Diabetes

The most common misunderstanding here is that type 2 diabetes is a blood sugar problem found by a blood sugar test. Glucose is the last thing to move. Insulin resistance develops first, the pancreas compensates by producing more insulin, and that extra insulin holds glucose inside the normal range for years. Standard testing can read normal throughout. By the time a fasting glucose crosses 100 mg/dL, the compensation is already failing, which is why so many people are told their labs are fine right up until they are told they have prediabetes.

What this area actually covers

The sequence matters more than any single diagnosis. Insulin resistance comes first and is not itself a diagnosis with an agreed test. Then comes impaired fasting glucose or impaired glucose tolerance, grouped under the label prediabetes. Then type 2 diabetes. The same underlying process also drives fatty liver, and often shows up alongside PCOS and obstructive sleep apnea, which is why those topics keep appearing in the same clinic visit.

The scale is not marginal. The CDC's national diabetes data, released in January 2026, put 40.1 million people, or 12.0 percent of the US population, with diabetes, and 115.2 million US adults with prediabetes. Of adults who have diabetes, 27.6 percent do not know it. Those are not rounding errors; they describe a condition that is usually silent when it is most treatable.

Where the standard workup goes wrong

The usual workup is one fasting glucose and one HbA1c drawn once a year. Both are late markers, and HbA1c in particular is an average that hides how a person actually handles food. Two failure modes follow. Insulin resistance goes unrecognised for years because nobody looked earlier than the glucose. And a rising HbA1c gets treated as a number to lower rather than a signal to ask what is driving it, so sleep apnea, a fatty liver, alcohol, a steroid course or an antipsychotic goes unaddressed while the medication list grows.

There is a third, more serious miss. An adult diagnosed with type 2 diabetes who is lean, who responds poorly to oral medication, or who deteriorates quickly may have latent autoimmune diabetes rather than type 2. Antibody testing settles it, and getting that wrong delays insulin in someone who needs it.

How to think about the decisions

The diagnostic thresholds are agreed lines drawn across a continuous risk gradient, not biological cliffs. A fasting glucose of 99 mg/dL is not meaningfully safer than 101 mg/dL. What the lines do is trigger action, which is their real purpose. The Diabetes Prevention Program showed what action achieves: participants in the lifestyle programme lowered their chance of developing type 2 diabetes by 58 percent, and those taking metformin by 31 percent, against placebo. The lifestyle target was modest, 7 percent body weight and 150 minutes of activity a week. In the 15 year follow-up the advantage persisted but narrowed, to 27 percent for lifestyle and 18 percent for metformin.

Two things here are genuinely contested. The prediabetes label itself is disputed: John Yudkin and Victor Montori argued in The BMJ in 2014 that the category medicalises an enormous population without proportionate benefit, while the American Diabetes Association retains it as a risk state that justifies intervention. Separately, fasting insulin and HOMA-IR are widely marketed as insulin resistance tests, yet no insulin measurement appears anywhere in the ADA diagnostic criteria, and HOMA-IR thresholds vary between assays and populations. It is a useful index, not a diagnosis.

What changed recently

The ADA published its Standards of Care in Diabetes 2026 on 8 December 2025. Several changes shift ordinary practice: continuous glucose monitoring is now recommended at diabetes onset for anyone who could benefit rather than being reserved for insulin users, obesity medication dosing is to be individualised, obesity treatment in type 1 diabetes gets dedicated guidance for the first time, and Mediterranean-style and low-carbohydrate eating patterns are named for type 2 diabetes prevention.

The answers below start with what insulin resistance is and how it is tested, move through the diagnostic numbers and what they trigger, then cover metformin, continuous glucose monitors, remission and the drivers that sit underneath the glucose. If you are holding a lab report, the threshold table above tells you which answer to open.